OriGene Technologies, a Rockville, MD-based life science company producing biotechnology products for the research and medical markets, recently received an investment of undisclosed amount.
Backers included Cathay Capital Private Equity, which made the investment through the Sino French Fund for SMEs (Sino French Fund), an investment vehicle designed to support the development of French and Chinese small and medium enterprises internationally, IDG Capital Partners and Mérieux Développement.
The company intends to use the funds to deepen its cooperation with global laboratories and grow its product sales in Europe.
Established in 1996 by Weiwu He, CEO, OriGene is a life science technology company which develops and markets products for research laboratories, diagnostic companies, clinics and hospitals. Its business line mainly focuses on the manufacture of biological reagents (including cDNA, proteins, and antibodies) providing technological solutions for the markets of in-vitro diagnosis and immunohistochemistry.